SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) is a clinical-stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in January 2018 through an initial public offering. Solid Biosciences focuses exclusively on developing gene therapies for Duchenne Muscular Dystrophy (DMD), a rare and devastating genetic muscle-wasting disease that primarily affects boys. The company is currently advancing two gene therapy candidates through clinical and preclinical development stages.